Catalyst Pharmaceutical Partners, Inc. Begins Enrollment For U.S. Phase II Clinical Trial Of CPP-109 In Patients With Methamphetamine Addiction

Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction and obsessive compulsive disorders, announced that it has begun enrollment for its randomized, double-blind, placebo-controlled U.S. Phase II clinical trial evaluating CPP-109 for the treatment of patients addicted to methamphetamine.

More: continued here

Filed under: Alcohol / Addiction / Illegal Drugs on July 4th, 2008